TD Cowen downgraded Arvinas (ARVN) to Hold from Buy without a price target following the cancellation of the vepdeg combo trials by the company’s partner Pfizer. TD previously thought vepdeg could be differentiated based on management’s comments, but it now believe this is “increasingly unlikely.” Further, the cancellation of the combo trials removes the largest market opportunity, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas price target lowered to $16 from $32 at Barclays
- Arvinas Reports Strong Q1 2025 Results and Strategic Shift
- Arvinas downgraded to Hold at Jefferies after Vepdeg development decision
- Arvinas downgraded to Hold from Buy at Jefferies
- Oppenheimer surprised by ‘hasty’ decision to cull frontline Vepdeg development